Prescription medicine
Tacrolimus Brand names: Prograf, Astagraf, Envarsus
Tacrolimus (Prograf) is a prescription medicine with an FDA approval on record since 1994. FDA's NDC Directory lists it from 33 generic labelers, and pharmacies paid $0.970 per gram (Tacrolimus 0.1% ointment) in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.); the NDA 50708 record on Drugs@FDA; every tacrolimus label on DailyMed.
Highlights of the record
FDA label of July 17, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
MALIGNANCIES AND SERIOUS INFECTIONS.
Increased risk for developing serious infections and malignancies with Tacrolimus or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 ) WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppressants that may lead to hospitalization or death.
Used for
From the label: indications and usageTacrolimus capsules are a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney or heart transplants, in combination with other immunosuppressants.
Forms and strengths
- 0.2 mg
- 0.5 mg
- 0.75 mg
- 1 mg
- 4 mg
- 5 mg
- 0.3 mg/g
- 1 mg/g
- 5 mg/ml
Capsule; gelatin-coated capsule; ointment; coated extended-release capsule; extended-release capsule.
On the market
- Earliest approval on file
- April 8, 1994 Prograf, Astellas; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 20 first August 10, 2009; 17 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 36 of which 33 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- August 30, 2028 Envarsus XR tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.970 per gram Tacrolimus 0.1% ointment
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 9 since 2012 4 Class I among all firms' recalls; latest December 23, 2024; 9 more by firms not listed as its makers
- FAERS reports
- 156,020 through July 30, 2026
What is tacrolimus used for?
From the label: indications and usageTacrolimus capsules are a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney or heart transplants, in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney, Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection, in adult and pediatric patients receiving allogeneic kidney transplant [see Clinical Studies ( 14.1 )], liver transplant [see Clinical Studies ( 14.2 )], or heart transplant [see Clinical Studies ( 14.3 )] in combination with other immunosuppressants. […]
Conditions named in the indications of tacrolimus's FDA labels, with every medicine labeled for each:
From other tacrolimus labelsEczema (atopic dermatitis): … therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic …
FDA pharmacologic class: Calcineurin Inhibitor Immunosuppressant.
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
What does the patient leaflet for tacrolimus say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about tacrolimus capsules?Tacrolimus capsules can cause serious side effects, including: • Increased risk of cancer. People who take tacrolimus capsules have an increased risk of getting some kinds of cancer, including skin and lymph gland cancer (lymphoma). • Increased risk of infection. Tacrolimus capsules is a medicine that affects your immune system. Tacrolimus capsules can lower the ability of your immune system to fight infections. Serious infections can happen in people receiving tacrolimus capsules that can cause death. Call your healthcare provider right away if you have any symptoms of an infection, including: • fever • muscle aches • sweats or chills • warm, red, or painful areas on your skin • cough or flu-like symptoms
From the patient leaflet: What should I avoid while taking tacrolimus capsules?While you take tacrolimus capsules you should not receive any live vaccines. • Limit the amount of time you spend in sunlight and avoid exposure to ultraviolet (UV) light, such as tanning machines. Wear protective clothing and use a sunscreen with a high sun protection factor (SPF). • Do not eat grapefruit or drink grapefruit juice during treatment with tacrolimus capsules.
From the patient leaflet: How should I store Tacrolimus Capsules?Tacrolimus capsules Store tacrolimus capsules at room temperature between 20°C to 25°C (68°F to 77°F). Keep tacrolimus capsules and all medicines out of the reach of children.
Source: FDA drug label (tacrolimus), Glenmark Pharmaceuticals Inc., USA, effective January 21, 2026 (SPL set 4b310c6b-e035-4e44-9573-4001d58b2ad5), via openFDA; the full label on DailyMed
Is there a generic for tacrolimus (Prograf)?
The FDA approved the first generic tacrolimus on August 10, 2009. 20 generic applications are approved; 17 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists tacrolimus from 33 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Prograf capsules; a patent listed only for Envarsus XR tablets runs to August 30, 2028. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1994 earliest approval on file
- 2009 first generic approved
- 2028 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for tacrolimus (Prograf)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.970 per gram (Tacrolimus 0.1% ointment), up 3% from $0.938 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Tacrolimus 0.5 mg capsule (immediate release) (generic)
- Astagraf xl 0.5 mg capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Tacrolimus 0.03% ointment | Generic | $0.927 per gram | n/a | +11% |
| Tacrolimus 0.1% ointment | Generic | $0.970 per gram | n/a | +3% |
| Tacrolimus 0.5 mg capsule (immediate release) | Generic | $0.123 per capsule | $3.68 | -30% |
| Tacrolimus 1 mg capsule (immediate release) | Generic | $0.153 per capsule | $4.60 | -9% |
| Tacrolimus 5 mg capsule (immediate release) | Generic | $0.688 per capsule | $20.64 | -16% |
| Astagraf xl 0.5 mg capsule | Brand | $2.88 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $86.45 | +4% |
| Astagraf xl 1 mg capsule | Brand | $5.71 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $171.27 | +4% |
| Prograf 0.2 mg granule packet | Brand | $5.02 per packet many times the lowest per-tablet cost; NADAC records the price, not why | n/a | +0.2% |
| Prograf 0.5 mg capsule | Brand | $3.66 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $109.77 | +2% |
| Prograf 1 mg capsule | Brand | $7.33 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $219.82 | +3% |
| Prograf 1 mg granule packet | Brand | $7.44 per packet many times the lowest per-tablet cost; NADAC records the price, not why | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has tacrolimus been recalled?
The FDA's Enforcement Report lists 18 recalls naming tacrolimus since 2012: 4 Class I (the most serious), 11 Class II, 3 Class III; 5 still ongoing. 9 of them are by firms that FDA's NDC Directory does not list as a maker of tacrolimus and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 23, 2024 | Class I | Astellas Pharma US Inc. | Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules |
| December 15, 2023 | Class II | Dr. Reddy's Laboratories, Inc. | Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules. |
| February 8, 2023 | Class II | Dr. Reddy's Laboratories, Inc. | Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules. |
| July 11, 2022 | Class III | Glenmark Pharmaceuticals Inc., USA | Defective Container: Tube split from side seam |
| April 15, 2022 | Class I | Valor Compounding Pharmacy, Inc DBA Valor Compounding … not a listed maker | Subpotent drug |
| December 22, 2020 | Class III | Strides Pharma Inc. | Failed Moisture Limits |
| March 23, 2020 | Class III | Mylan Pharmaceuticals Inc. | Presence of foreign tablet/capsule - Potential presence of commingled one Tacrolimus 1 mg capsule in 5 mg bottles. |
| February 9, 2018 | Class II | American Pharmaceutical Ingredients LLC not a listed maker | CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the tacrolimus label say about other medicines?
The tacrolimus label names 43 other medicines in its interaction, contraindication or warning sections. The labels of 51 other medicines name tacrolimus. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amiodarone | drug interactions | Drug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Amphotericin b | warnings and precautions | The risk for nephrotoxicity may increase when tacrolimus is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors … |
| Cannabidiol | drug interactions | Decreased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed. ( 5.11 , 7.2 ) Therapeutic drug monitoring and dose reduction for tacrolimus should be considered when tacrolimus is co-administered with cannabidiol ( 5.17 , 7.3 ). |
| Carbamazepine | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inducers 3: Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John's wort; Drug Interaction Effect: May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see)].; … |
| Caspofungin | drug interactions | Caspofungin May decrease tacrolimus whole blood trough concentrations. |
| Castor oil | contraindications | CONTRAINDICATIONS Hypersensitivity to tacrolimus or HCO-60 (polyoxyl 60 hydrogenated castor oil). ( 4 ) Tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. |
| Chloramphenicol | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inhibitors 3: Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra … |
| Cimetidine | drug interactions | Drug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Cisplatin | warnings and precautions | The risk for nephrotoxicity may increase when tacrolimus is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors … |
| Clarithromycin | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inhibitors 3: Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra … |
| Clotrimazole | drug interactions | Drug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Cobicistat | drug interactions | … antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, Schisandra sphenanthera extracts, cobicistat; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). … |
| Cyclosporine | drug interactions | DRUG INTERACTIONS Mycophenolic Acid Products: Can increase MPA exposure after crossover from cyclosporine to tacrolimus; monitor for MPA-related adverse reactions and adjust MMF or MPA dose as needed. ( 7.1 ) Nelfinavir and Grapefruit Juice: |
| Danazol | drug interactions | Drug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
Every other medicine the tacrolimus label names
| Medicine named | Section | What the label says |
|---|---|---|
| Diltiazem | drug interactions | … erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Erythromycin | drug interactions | Drug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine … |
| Fluconazole | drug interactions | Drug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine … |
| Ganciclovir | warnings and precautions | … concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). |
| Imatinib | drug interactions | … azole antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase … |
| Itraconazole | drug interactions | … boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir … |
| Ketoconazole | drug interactions | … azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera … |
| Lansoprazole | drug interactions | … nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase the risk … |
| Letermovir | drug interactions | … (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations … |
| Methylprednisolone | drug interactions | Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. |
| Metoclopramide | drug interactions | Drug/Substance Class or Name: Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and … |
| Midazolam | drug interactions | … inhibitor/inducer data, or based on drug- drug interaction studies with midazolam (sensitive CYP3A probe substrate). |
| Mycophenolic acid | drug interactions | DRUG INTERACTIONS Mycophenolic Acid Products: Can increase MPA exposure after crossover from cyclosporine to tacrolimus; monitor for MPA-related adverse reactions and adjust MMF or MPA dose as … |
| Nefazodone | drug interactions | … antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts; … |
| Nelfinavir | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inhibitors 3: Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole … |
| Nicardipine | drug interactions | … calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Nifedipine | drug interactions | … fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Nilotinib | drug interactions | … antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase the risk … |
| Omeprazole | drug interactions | … amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase the risk of serious … |
| Phenobarbital | drug interactions | … rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John's wort; Drug Interaction Effect: May decrease tacrolimus whole blood trough concentrations and … |
| Phenytoin | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inducers 3: Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John's wort; … |
| Posaconazole | drug interactions | … telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone … |
| Prednisone | drug interactions | Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. |
| Rifabutin | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inducers 3: Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John's wort; … |
| Rifampin | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inducers 3: Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John's wort; … |
| Ritonavir | drug interactions | Drug/Substance Class or Name: Strong CYP3A Inhibitors 3: Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole … |
| Sirolimus | warnings and precautions | Observe patients receiving tacrolimus injection for signs and symptoms of anaphylaxis. ( 5.9 ) Not recommended for use with sirolimus: |
| Verapamil | drug interactions | … (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; … |
| Voriconazole | drug interactions | … nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol) … |
Other labels that name tacrolimus
- Adefovir dipivoxil
- Afatinib
- Amiloride
- Amlodipine
- Atazanavir
- Belatacept
- Clozapine
- Darunavir
- Deferasirox
- Dexlansoprazole
- Dibasic and monobasic
- Efavirenz
- Elbasvir and grazoprevir
- Enzalutamide
- Esomeprazole
- Etravirine
- Everolimus
- Fenofibrate
- Fenofibric acid
- Fosamprenavir
- Foscarnet
- Isavuconazonium
- Ivacaftor
- Levamlodipine
- Maribavir
- Metronidazole
- Mifepristone
- Nevirapine
- Palbociclib
- Pimozide
- Potassium chloride
- Potassium phosphate dibasic and potassium phosphate monobasic
- Quizartinib
- Rabeprazole
- Ranolazine
- Sevelamer
- Sodium zirconium cyclosilicate
- Spironolactone
- Tigecycline
- Tinidazole
- Tofacitinib
- Valganciclovir
- Ziprasidone
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
What do FAERS reports show for tacrolimus?
The FDA Adverse Event Reporting System holds 156,020 reports that list tacrolimus among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 25,784 are coded as a death and 62,864 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as tacrolimus?
5 other medicines are given the same way (oral) and in the same FDA class as tacrolimus or labeled mainly for the same use (organ transplant rejection), the same class first. Organ transplant rejection lists all 13 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Cyclosporine | Organ transplant rejection | 8 labelers | $0.314 per unit 25 mg | No current entry |
| Mycophenolate mofetil | Organ transplant rejection | 30 labelers | $0.138 per capsule 250 mg capsule | No current entry |
| Mycophenolic acid | Organ transplant rejection | 16 labelers | $0.0996 per tablet 180 mg tablet | No current entry |
| Sirolimus | Organ transplant rejection | 18 labelers | $0.723 per tablet 1 mg tablet | No current entry |
| Azathioprine | Organ transplant rejection | 16 labelers | $0.124 per tablet 50 mg tablet | No current entry |
Every medicine labeled for the same conditions as tacrolimus
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does tacrolimus compare with medicines for the same use?
9 side-by-side pages set tacrolimus beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to tacrolimus
- 5 medicines for the same use
- Other calcineurin inhibitor immunosuppressants
- the pharmacologic class, with prices and generics
- Tacrolimus side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other